Lumida
/TRDA
⌘K
Entrada Therapeutics Inc

Entrada Therapeutics Inc

TRDA
$6.80USD+5.92%+0.38 today

MARKET CAP

264.8M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $7

52W RANGE

$5
$16

AI Summary

Stalk
StalkMedium

Price has formed a bullish pivot point above the 9EMA and 20EMA through the flattening 50 SMA, signaling structural repair and medium-term mean reversion opportunity within an overall downtrend. However, short-term extension and RSI near overbought levels suggest waiting for a clean pullback into the rising EMAs near the recent support zone before committing. Patience for a retracement into the $7.00–$7.20 area aligns with the COMP strategy’s emphasis on confirmation and controlled engagement.

  • Current $7.26 vs. $17.50 average analyst target (~140% upside)
  • Up 14.5% over two weeks and 6.9% jump on Aug 3 reflects strong momentum
  • Negative earnings yield and weak profitability suggest ongoing cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$129.0M$210.8M$25.4M
YoY %+63.4%-87.9%
P / Sales3.9x3.2x16.7x
EV / Sales5.1x3.2x16.0x
Gross Profit, Adj.$129.0M$210.8M$25.4M
YoY %+63.4%-87.9%
Margin %100.0%100.0%100.0%
EV / Gross Profit5.1x3.2x16.0x
EBITDA, Adj.$-321,000$50.8M$-153.8M
YoY %+99.7%+15920.6%-402.9%
Margin %-0.2%24.1%-605.0%
EV / EBITDA-2058.0x13.2x-2.6x
EBIT$-3.2M$47.0M$-157.9M
YoY %+96.7%+1586.7%-435.9%
Margin %-2.5%22.3%-621.1%
EV / EBIT-208.9x14.3x-2.6x
Net Income$-6.7M$65.6M$-143.8M
YoY %+92.9%+1081.7%-319.0%
Net Margin-5.2%31.1%-565.5%
EPS (GAAP)-$0.20$1.68-$3.47
YoY %+93.4%+940.0%-306.5%